MEDNAX Inc (MD) Expected to Earn FY2018 Earnings of $3.92 Per Share

MEDNAX Inc (NYSE:MD) – Jefferies Group boosted their FY2018 earnings estimates for shares of MEDNAX in a research note issued to investors on Monday. Jefferies Group analyst B. Tanquilut now forecasts that the company will post earnings of $3.92 per share for the year, up from their prior forecast of $3.27. Jefferies Group currently has a “Hold” rating and a $50.00 target price on the stock.

Several other analysts also recently issued reports on MD. Robert W. Baird increased their price objective on shares of MEDNAX from $48.00 to $54.00 and gave the company a “neutral” rating in a research report on Friday. Stephens set a $62.00 price objective on shares of MEDNAX and gave the company a “buy” rating in a research report on Thursday. Mizuho set a $49.00 price objective on shares of MEDNAX and gave the company a “hold” rating in a research report on Wednesday, January 24th. Stifel Nicolaus reiterated a “hold” rating and set a $56.00 target price on shares of MEDNAX in a research note on Wednesday, January 24th. Finally, Zacks Investment Research upgraded MEDNAX from a “hold” rating to a “buy” rating and set a $60.00 target price for the company in a research note on Tuesday, January 23rd. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $54.75.

Shares of MEDNAX (MD) traded up $0.81 during trading hours on Thursday, reaching $53.37. 768,785 shares of the company’s stock traded hands, compared to its average volume of 885,721. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.37 and a quick ratio of 1.37. MEDNAX has a one year low of $40.56 and a one year high of $72.13. The firm has a market capitalization of $4,920.00, a P/E ratio of 15.86, a price-to-earnings-growth ratio of 1.40 and a beta of 0.31.

MEDNAX (NYSE:MD) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.83 by $0.04. MEDNAX had a net margin of 7.76% and a return on equity of 10.80%. The company had revenue of $910.82 million during the quarter, compared to the consensus estimate of $884.55 million. During the same quarter last year, the company earned $1.00 earnings per share. MEDNAX’s revenue for the quarter was up 9.6% on a year-over-year basis.

A number of hedge funds have recently bought and sold shares of the business. Toronto Dominion Bank boosted its position in MEDNAX by 19,942.3% during the 3rd quarter. Toronto Dominion Bank now owns 723,928 shares of the company’s stock worth $31,211,000 after acquiring an additional 720,316 shares during the period. JPMorgan Chase & Co. raised its stake in shares of MEDNAX by 987.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 756,215 shares of the company’s stock valued at $32,607,000 after acquiring an additional 686,678 shares in the last quarter. Prudential Financial Inc. raised its stake in shares of MEDNAX by 976.9% in the 3rd quarter. Prudential Financial Inc. now owns 641,057 shares of the company’s stock valued at $27,642,000 after acquiring an additional 581,527 shares in the last quarter. Thompson Siegel & Walmsley LLC raised its stake in shares of MEDNAX by 19.7% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 2,598,925 shares of the company’s stock valued at $112,065,000 after acquiring an additional 428,184 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of MEDNAX by 74.9% in the 4th quarter. Wells Fargo & Company MN now owns 838,882 shares of the company’s stock valued at $44,830,000 after acquiring an additional 359,288 shares in the last quarter. Institutional investors own 98.67% of the company’s stock.

In related news, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total transaction of $154,740.00. Following the transaction, the insider now directly owns 35,569 shares in the company, valued at $1,834,649.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.40% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “MEDNAX Inc (MD) Expected to Earn FY2018 Earnings of $3.92 Per Share” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.com-unik.info/2018/02/09/mednax-inc-md-expected-to-earn-fy2018-earnings-of-3-92-per-share.html.

MEDNAX Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit